The effects of delta-9-tetrahydrocannabinol on the dopamine system
Bottom Line
The Backstory
The first time you smoke cannabis, the high feels effortless. Music sounds better. Food tastes incredible. Everything is interesting. A year of daily use later, you're smoking twice as much for half the effect, nothing sounds quite as good sober, and getting off the couch requires conscious effort.
Most people attribute this to willpower or personality. Michael Bloomfield's team, in a landmark review published in Nature, showed it's neurochemistry. Specifically, it's what THC does to your dopamine system — first flooding it, then systematically blunting it.
The Dopamine Paradox
The central finding of this review is a paradox that explains nearly everything about the chronic cannabis experience:
This is the same pattern seen with other substances — alcohol, nicotine, opioids, stimulants — but cannabis produces a milder version. The brain's response to chronic dopamine overstimulation is always the same: turn down the machinery. Fewer dopamine receptors. Lower dopamine synthesis. Blunted release. The technical term is neuroadaptation. The lived experience is needing more weed for less effect.
How THC Reaches the Dopamine System
THC doesn't bind to dopamine receptors directly. The pathway is indirect, working through the endocannabinoid system:
The Human Evidence
Bloomfield's team synthesized data from PET imaging studies in human cannabis users. The findings were consistent:
In Bloomfield's own 2014 PET study, 14 regular cannabis users showed reduced dopamine synthesis capacity in the striatum — and the degree of reduction correlated directly with self-reported apathy. Lower dopamine production mapped onto lower motivation. This wasn't a personality trait — it was measurable neurochemistry.
Correlated
dopamine synthesis capacity in the striatum was inversely correlated with apathy scores in cannabis users — measured by [18F]-DOPA PET imaging. Users with the lowest dopamine synthesis reported the most amotivation.
This is the biological mechanism behind what's colloquially called 'stoner laziness.' It's not a character flaw or a lack of discipline — it's a measurable reduction in the neurochemical substrate of motivation. And it's the same basic process that occurs with any substance that chronically elevates dopamine.
Bloomfield et al. (2014), Psychopharmacology 231:2251-9
What This Means for Daily Users
If you've been using cannabis daily and noticed that things don't feel as rewarding as they used to — food is less exciting, music less moving, accomplishments less satisfying — this review explains why. Your dopamine system has downregulated in response to chronic THC stimulation. The world hasn't changed. Your reward circuitry has.
Myth vs. Reality
Cannabis permanently damages the dopamine system — once you've blunted it, it's gone.
The dopamine blunting from chronic cannabis use appears moderate compared to stimulants and reversible with sustained abstinence. While the review notes limited longitudinal data, the available evidence suggests dopamine function recovers over weeks to months after cessation. The CB1 receptor recovery data (28 days to normalization per D'Souza et al., 2016) supports this timeline, since CB1 recovery upstream should allow downstream dopamine normalization.
The Evidence
PET studies show blunting in current users but limited data on post-cessation recovery. CB1 receptors normalize by 28 days. Clinical observation and the D'Souza PET data suggest dopamine-related symptoms (anhedonia, amotivation) improve over a similar timeline.
Bloomfield et al. (2016), Nature; D'Souza et al. (2016), Biol Psychiatry
This is why the first few weeks after quitting feel so flat. Your dopamine system is running on reduced capacity. The natural pleasures of daily life — which were always producing dopamine, just less noticeably while THC was flooding the system — feel muted because your dopamine machinery is still calibrating back to normal. The recovery timeline is real, and the reward system does come back.
The Researchers
This review was published in Nature — the most prestigious scientific journal in the world — which speaks to the importance the scientific community places on understanding cannabis-dopamine interactions. The co-author list is notable:
Michael Bloomfield at Imperial College London has conducted the key PET imaging studies in human cannabis users. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA) and one of the most influential addiction researchers alive, brought her extensive expertise on dopamine and substance use disorders. Oliver Howes, a leading figure in psychosis and dopamine research at King's College London, provided the psychiatric context.
The collaboration of these four researchers produced what is arguably the definitive review of how THC affects the dopamine system — synthesizing decades of animal pharmacology, human neuroimaging, and clinical observation into a coherent picture.
Cite this study
Bloomfield, Michael A P; Ashok, Abhishekh H; Volkow, Nora D; Howes, Oliver D. (2016). The effects of delta-9-tetrahydrocannabinol on the dopamine system. Nature, 539(7629), 369-377. https://doi.org/10.1038/nature20153